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Abstract
Prostate cancer frequently metastasizes to the bone,
and the treatment outcome for metastatic prostate
cancer has been disappointing so far. Dietary genistein,
derived primarily from soy product, has been proposed
to be partly responsible for the low rate of prostate
cancer in Asians. Our previous studies have shown that
genistein elicits pleiotropic effects on prostate cancer
cells, but there are no studies documenting compre-
hensive gene expression profiles and antitumor effects
of dietary genistein on human prostate cancer grown in
human bone environment. In this study, we investigated
the effects of genistein on PC3 prostate cancer cells
and experimental PC3 bone tumors created by injecting
PC3 cells into human bone fragments previously
implanted in severe combined immunodeficient (SCID)
mice (SCID human model). We found that genistein
significantly inhibited PC3 bone tumor growth using
both prevention and intervention strategies. By using
microarray and real-time polymerase chain reaction
technology, we found that genistein regulated the
expression of multiple genes involved in the control of
cell growth, apoptosis, and metastasis both in vitro and
in vivo. For example, the expression of various metal-
loproteinases (MMPs) in PC3 bone tumors was inhibited
by genistein treatment, whereas osteoprotegerin was
upregulated. MMP immunostaining and transfection
experiments also demonstrated that MMP-9 expression
was inhibited in PC3 cells in vitro and PC3 bone tumors
in vivo after genistein treatment. These results, partic-
ularly the in vivo results, demonstrate that dietary
genistein may inhibit prostate cancer bone metastasis
by regulating metastasis-related genes. Genistein may
thus be a promising agent for the prevention and/or
treatment of prostate cancer.
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Introduction
Prostate cancer is the second leading cause of cancer-
related deaths in men in the United States with an estimated
220,900 new cases and 28,900 deaths in 2003 [1]. Up to 30%
of patients with prostate cancer undergoing radical prostatec-
tomy will relapse, often as a result of micrometastatic disease
present at the time of surgery [2,3]. Bone metastasis is com-
mon in advanced prostate cancer and causes considerable
morbidity including pain, pathologic fractures, spinal cord com-
pression, and disability. Systemic androgen deprivation is
initially effective in treating metastasis; however, the metastatic
deposits ultimately become refractory to hormonal or chemo-
therapeutic manipulations and continue to grow. Therefore,
there is a tremendous need for the development of mechanism-
based strategies for the treatment of prostate cancer. To
discover new strategies, it is important to explore the precise
mechanisms of cancer cell metastasis to the bone and the
molecular mechanism(s) by which new agents exert their
inhibitory effects on cancer metastasis.
Because of the suitable microenvironment of the bone for
colonization and growth of metastatic tumors, the bone has
long been recognized as a common target organ for prostate
cancer [4]. The preference of prostate cancer for the bone is
due to the results of cancer cell interactions with multiple other
cells and molecules in the local microenvironment. Among
these molecules, matrix metalloproteinases (MMPs), receptor
activator of NF-nB (RANK), receptor activator of NF-nB ligand
(RANKL), and osteoprotegerin (OPG) are more evidently
involved in the cancer cell bone metastases [5–9]. The matrix
MMPs are a family of proteases that play important roles in the
degradation of extracellular matrix and the release or activation
of growth factors [10,11]. MMPs are upregulated in virtually all
human and animal tumors as well as in most tumor cell lines
[11,12]. In several cases, the stage of tumor progression is
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positively correlated with the expression of MMP family
members. Changes in MMP levels can markedly affect the
invasive behavior of tumor cells and their ability to metasta-
size in experimental animal models [13]. With regard to bone
metastasis, we and others have demonstrated that inhibition
of MMP activity can disrupt the ‘‘vicious cycle’’ between bone
tumor growth and bone matrix remodeling in experimental
prostate and breast cancer bone metastasis [14,15]. Be-
cause bone matrix remodeling is important in bone metas-
tasis, much attention has been focused on the osteoclasts
[16]. Osteoclastic activity is believed to be a critical target for
therapy against bone metastasis, and RANK, RANKL, and
OPG are known to be the major molecules that modulate
osteoclast differentiation and maturation. Therefore, these
molecules have received much attention in the area of bone
metastasis research [5].
In contrast to the population in western countries, Asian
men who consume a traditional diet high in soy products
have a relatively low incidence and mortality of prostate
cancer, suggesting that a high intake of soy products may
protect men against prostate cancer [17]. Genistein is a
prominent isoflavonoid found in soy products, and has been
proposed to be partly responsible for the low rate of prostate
cancer in Asian men [17,18]. Genistein has been identified
as an inhibitor of protein tyrosine kinases, which play key
roles in cell growth and apoptosis. Studies from our labora-
tory and others have found that genistein can inhibit cancer
cell growth, induce apoptosis, modulate the expression of
genes related to the apoptotic pathway, and inhibit NF-nB
and Akt activation in cancer cells [18–21]. In the TRAMP
model, dietary genistein supplementation, yielding serum
levels of genistein comparable with those found in Asian
men on a regular soy diet, reduced the incidence of poorly
differentiated prostate carcinoma [22]. Similarly, dietary soy
significantly reduced tumor cell proliferation, increased apo-
ptosis, and reduced microvessel density in PC3 xenograft
tumors in severe combined immunodeficient (SCID) mice
[23]. Genistein also can inhibit the in vitro invasive potential
of human prostate cancer cell lines, suggesting that genis-
tein could inhibit the metastatic growth of prostate cancer
[24]. Moreover, our studies using microarray have shown
that genistein can inhibit prostate cancer cells in vitro by
regulating the expression of genes, which are critically
involved in cell growth, cell cycle, cell signal transduction,
angiogenesis, tumor cell invasion, and metastasis [25,26].
However, the role of genistein in the inhibition of invasion and
metastasis and the comprehensive gene expression profiles
of human prostate cancer grown in the human bone envi-
ronment in vivo have not been documented. In this study, we
have utilized the SCID human (SCID-hu) model of prostate
cancer bone metastasis [27] to determine the effect of
genistein in vivo and investigated the gene expression
profiles of SCID-hu prostate cancer bone tumors altered by
dietary genistein using microarray, real-time polymerase
chain reaction (PCR), and other techniques. The purpose
of our current investigation: was 1) to determine the effects of
genistein on prostate cancer cells in vitro; 2) to determine the
effects of genistein on prostate cancer bone tumor growth
in vivo; 3) to determine the alterations in gene expression
profiles by genistein treatment in both in vitro and in vivo
studies; and 4) to compare the gene expression profiles of
PC3 bone tumors and PC3 subcutaneous tumors in SCID
mice so as to better understand the molecular mechanism(s)
by which genistein exerts its antimetastatic effect on prostate
cancer cells.
Materials and Methods
Cell Culture and Cell Growth Inhibition
PC3 human prostate cancer cells (ATCC, Manassas, VA)
were cultured in RPMI 1640 media (Invitrogen, Carlsbad,
CA) supplemented with 10% fetal bovine serum and 1%
penicillin and streptomycin in a 5% CO2 atmosphere at
37jC. Genistein (Toronto Research Chemicals, North York,
Ontario, Canada) was dissolved in 0.1 M Na2CO3 to make a
10-mM stock solution and was added directly to the culture
media at different concentrations. The PC3 cells were seed-
ed at a density of 1  103/well in 96-well culture dishes. After
24 hours, the cells were treated with 5, 15, 30, and 50 mM
genistein or 0.5 mM Na2CO3 (vehicle control). Cells treated
with genistein or Na2CO3 for 1 to 3 days were incubated with
MTT (0.5 mg/ml; Sigma, St. Louis, MO) at 37jC for 4 hours
and then with DMSO at room temperature for 1 hour. The
spectrophotometric absorbance of the samples was deter-
mined by using ULTRA Multifunctional Microplate Reader
(TECAN, Durham, NC) at 495 nm.
Animal Care and Human Bone Implantation
Male homozygous CB-17 scid/scid mice, aged 4 weeks,
were purchased from Taconic Farms (Germantown, NY).
The mice were maintained according to the National Insti-
tutes of Health standards established in the ‘‘Guidelines for
the Care and Use of Experimental Animals,’’ and all exper-
imental protocols were approved by the Animal Investigation
Committee of Wayne State University (Detroit, MI). Human
male fetal bone tissue was obtained by a third-party,
nonprofit organization (Advanced Bioscience Resources,
Alameda, CA) and written informed consent was obtained
from the donor, consistent with regulations issued by each
state involved and the federal government. Isoflurane anes-
thesia was used during all surgical procedures. After 1 week
of acclimatization, the mice were implanted with a single
human fetal bone fragment as described previously [27].
Production of Prostate Cancer Bone Tumors and Genistein
Treatment
Suspensions of PC3 cells (1  105 cells in a volume of
20 ml of RPMI 1640 medium) were injected intraosseously by
insertion of a 27-gauge needle through the mouse skin
directly into the marrow surface of the previously implanted
bone. The mice were divided into three groups: prevention
(n = 7), intervention (n = 7), and control (n = 6) groups. In the
prevention group, the mice were fed a genistein-containing
diet (1 g/kg diet) beginning on the day of intraosseous tu-
mor cell injection. The mice in the intervention group were
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given the genistein-containing diet as soon as the majority of
the bone implants began to enlarge (now called a ‘‘bone
tumor’’) as determined by caliper measurements (23rd day
after cancer cell injection). The control mice received the
exact same diet (AIN76A; Purina Test Mills, Richmond, IN)
but without genistein. The volume of the bone tumor in each
group was determined by twice-weekly caliper measure-
ments according to the formula ab2 / 2, where a = length
and b = cross-sectional diameter. For statistical analysis, log
transformation and linear mixed effect regression model
were used to evaluate the significance of difference in tumor
volume and rate of tumor volume growth between groups.
The procedure of Holm [28] was used to adjust for multiple
comparisons.
The mice were sacrificed on the 59th day after cancer cell
injection. Blood samples collected at sacrifice were sub-
jected to quantification of plasma genistein. Bone tumors
were removed and subjected to ex vivo imaging on a Lo-Rad
M-IV mammography unit (Lorad, Danbury, CT) using a mag-
nified specimen technique. Images were developed using a
Kodak 2000 screen and radiography film (Kodak, Rochester,
NY). Two bone tumors from each group were subjected to
microarray analysis and immunostaining. As a microenviron-
ment control, PC3 subcutaneous tumors were created in
SCID mice by injecting 5  106 cells. The PC3 subcutane-
ous tumors were harvested after 30 days.
Quantification of Plasma Genistein Using LC/ES-MS
Genistein in the plasma from mice was quantified using
the method published previously [29]. Solid-phase extraction
of total plasma isoflavones was performed following enzy-
matic deconjugation. Genistein in the samples was mea-
sured using isotope dilution LC-ES/MS with d4-genistein
internal standards. The method detection limit was approx-
imately 0.02 mM and the interassay and intra-assay precision
and accuracy was ±5% to ±10%. Quality control procedures
included concurrent analysis of isoflavone-fortified human
plasma and blank plasma.
Microarray Analysis for Gene Expression Profiles
PC3 cells treated with 50 mM genistein or 0.5 mM
Na2CO3 for 6, 36, and 72 hours; PC3 bone tumors from
each group; and PC3 subcutaneous tumors were subjected
to microarray analysis. Total RNA from each sample was
isolated by Trizol (Invitrogen) and purified by RNeasy Mini
Kit and RNase-free DNase Set (QIAGEN, Valencia, CA)
according to the manufacturer’s protocol. cDNA for each
sample was synthesized by using Superscript cDNA Syn-
thesis Kit (Invitrogen) with T7-(dT)24 primer in place of the
oligo(dT) provided in the kit. Then, the biotin-labeled cRNA
was transcripted in vitro (IVT) from cDNA by using BioArray
HighYield RNA Transcript Labeling Kit (ENZO Biochem,
New York, NY), and purified by RNeasy Mini Kit (QIAGEN,
Valencia, CA). The purified cRNA was fragmented and
applied to Human Genome U95 or U133A Array (Affymetrix,
Santa Clara, CA). After hybridization, washing, and staining,
the arrays were scanned. The gene expression levels of
samples were normalized and analyzed by using Microarray
Suite, MicroDB, and Data Mining Tool software (Affymetrix).
Clustering and annotation of the gene expression were
analyzed by using Cluster, TreeView [30], Onto-Express
[31], and GenMAPP (www.genmapp.org).
Reverse Transcription –Polymerase Chain Reaction
(RT–PCR) Analysis for Gene Expression
The total RNA prepared for microarray was also sub-
jected to real-time PCR using the method published previ-
ously [26]. Briefly, 2 mg of total RNA from each sample was
subjected to reverse transcription using Superscript first-
strand cDNA synthesis kit (Invitrogen). Real-time PCR reac-
tions were then carried out in a total of 25 ml of reaction
mixture (2 ml of cDNA, 12.5 ml of 2 SYBR Green PCR Mas-
ter Mix, 1.5 ml of 5 mM of each specific gene primer, and 7.5 ml
of H2O) in an ABI Prism 7700 Sequence Detection System
(Applied Biosystems, Foster City, CA). The sequences of
primers used in RT–PCR reaction have been described
previously [25]. The PCR program was initiated by 10 min-
utes at 95jC before 40 thermal cycles, each of 15 seconds at
95jC and 1 minute at 60jC. Data were analyzed according
to the comparative Ct method and were normalized by
GAPDH expression in each sample. Melting curves for each
PCR reaction were generated to ensure the purity of the
amplification product.
Reporter Gene Constructs and Transfection
Matrix metalloproteinase-9-chloramphenicol acetyltrans-
ferase (MMP-9–CAT) containing a nuclear factor-kappa B
(NF-nB) binding site in the sequence of MMP-9 promoter
was generously provided by Dr. Douglas Boyd (MD Ander-
son Cancer Center, Houston, TX). The MMP-9–CAT or
empty vector was transiently cotransfected with CMV-b-
galactosidase into PC3 cells using the LipofectAMINE
method (Invitrogen). After incubation for 5 hours, the trans-
fected cells were washed and incubated overnight with RPMI
1640 media (Invitrogen) supplemented with 10% fetal bovine
serum followed by treatment with genistein for 36 hours.
Subsequently, the CAT activities in the samples were mea-
sured by using CAT ELISA system (Roche, Palo Alto, CA)
and b-Galactosidase Enzyme Assay System (Promega,
Madison, WI) in an ULTRA Multifunctional Microplate
Reader (TECAN).
Immunohistochemical Staining for MMP-9
Freshly harvested tumors grown in the implanted bones
were fixed in 10% buffered formalin, decalcified, embedded,
and sectioned. The paraffin sections of tumor were depar-
affinized, then rehydrated through a graded alcohol series.
Slides were placed in 10 mM citrate buffer (pH 6.0) and
boiled by microwave heating for 3 minutes. Nonspecific
sites were blocked by incubation with Superbloc (ScyTek,
Logan, UT). Sections were incubated with anti–MMP-9
(5 mg/ml in a mixture of PBS and 2% bovine serum albumin;
Calbiochem, La Jolla, CA) monoclonal antibodies for 45
minutes at room temperature. Control slides received no
primary antibody. Sections were then incubated with rabbit
anti–mouse immunoglobulin G (1:40 dilution), followed by
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alkaline phosphatase/anti–alkaline phosphatase monoclo-
nal antibody (APAAP) (1:40 dilution). Positive immunoreac-
tive sites were visualized with the Sigma Fast Red (Sigma)
substrate. Sections were briefly counterstained with hema-
toxylin and mounted in aqueous medium.
Results
Cell Growth Inhibition by Genistein
PC3 prostate cancer cells were treated with 0 to 50 mM
genistein over 3 days. The effect of genistein on the prolif-
eration of PC3 cells is depicted in Figure 1. Treatment of
PC3 cells with genistein resulted in a dose- and time-depen-
dent inhibition of cell proliferation as previously observed
[26], demonstrating an inhibitory effect of genistein on
PC3 prostate cancer cell growth in vitro. We further investi-
gated whether or nor genistein could inhibit PC3 cell growth
in vivo in the SCID-hu model of human prostate cancer bone
metastasis.
Inhibition of Bone Tumor Growth and Osteolysis by
Genistein
The PC3 cells were injected into a human bone fragment
previously implanted in SCID mice, and expansion of the
bone implant into a bone tumor was followed by serial caliper
measurements. The concentration of plasma genistein in the
mice from both the prevention and intervention groups was
significantly higher compared to control (Table 1), suggest-
ing the bioavailability of genistein from the diet in these
mice. It is important to note that the mean concentration of
plasma genistein in the mice fed genistein diet is in the range
(1.4 ± 0.7 to 4.09 ± 0.94 mM) of plasma genistein found in
populations consuming foods rich in isoflavones [32,33]. We
found that dietary genistein significantly inhibited prostate
cancer bone tumor growth and osteolysis in SCID-hu mice
(Figure 2), demonstrating an inhibitory effect of genistein in
an in vivo model of bone metastasis. The statistical analysis
indicated that compared to the control group, bone tumor
growth rate was significantly lower in both the prevention
(PV .0001) and intervention (P = .0003) groups, and the rate
in the prevention group was lower than in the intervention
group. Log tumor volume growth rate in the prevention group
was 34% of the growth rate in the control group, whereas the
rate in the intervention group was 70% of that in the controls.
To examine the alteration of gene expression induced by
dietary genistein, we determined the gene expression pro-
files of PC3 bone tumors and PC3 subcutaneous tumors in
the dietary genistein and control groups.
Regulation of mRNA Expression by Genistein Treatment
In PC3 cells grown in culture, genistein regulated the
expression of genes that are critically involved in the control
of cell growth, cell cycle, apoptosis, cell signaling transduc-
tion, angiogenesis, tumor cell invasion, and metastasis [26].
In this in vivo study, microarray analysis also showed that
the gene expression in PC3 bone tumors was dramatically
altered by genistein treatment (Table 2A). It appears that
genistein altered gene expression profiles more significantly
in the prevention group than in the intervention group,
corresponding with more inhibition of tumor growth in the
prevention group. The genes with altered expression in PC3
bone tumors were subjected to cluster analysis according to
their biologic function using Onto-Express and GenMAPP
computerized annotation. It is important to note that the data
analysis software does not allow finding out howmany genes
there are in each categorized cluster in a whole gene chip.
We found that genistein in vivo–regulated some genes that
are involved in the regulation of cell cycle, apoptosis, signal
transduction, oncogenesis, chemotaxis, transcription, and
protein biosynthesis (Tables 2B and 3, Figure 3). This is
the first report regarding gene expression profiles altered
by genistein in vivo. Interestingly, we also found that genis-
tein regulated the expression of bone metastasis–related
genes with downregulation of MMPs and upregulation of
OPG (Tables 3 and 4, Figure 3). However, the significance
of many of these genes in the cause-and-effect relation-
ships between deregulated genes and genistein-induced
biologic effects in prostate cancer needs further in-depth
investigation.
Inhibition of MMP Expression by Genistein Treatment
Microarray analysis showed that genistein inhibited the
expression of MMP-9 in PC3 cells in culture [25] and the
expression of various MMPs in PC3 bone tumors (Figure 4,
Table 4). Real-time RT–PCR was conducted to confirm
the alteration in the expression of MMP-9. The results of
RT–PCR analysis for MMP-9 mRNA expression were in
agreement with the microarray data in general (Figure 5),
although the fold changes in expression level were not
exactly equal. Our gene transfection experiments showed
Figure 1. Inhibitory effects of genistein on the growth of PC3 cells in culture.
PC3 cells were treated with 5, 15, 30, and 50 M genistein for 24, 48, and 72
hours. (*P < .05, n = 3, cell proliferation index: the percentage of sample
absorbance versus control absorbance).
Table 1. The Concentration of Plasma Genistein in the SCID-hu Mice.
Group Concentration of Genistein (mM) n P
Control 0.0065 ± 0.0159 6
Prevention 0.8261 ± 0.3684 7 <.01
Intervention 1.6976 ± 1.2469 7 <.01
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that CAT activity of the MMP-9 promoter decreased after
genistein treatment (Figure 6). Together, these results sug-
gest that genistein treatment downregulates the transcription
of several MMPs, particularly MMP-9. In order to verify
whether the alteration of MMP-9 at the level of transcription
ultimately resulted in alterations in protein levels or nor, we
conducted immunohistochemical analysis for MMP-9 pro-
tein. The MMP-9 immunostaining showed that MMP-9 pro-
tein was decreased in PC3 bone tumors in SCID-hu mice
receiving the genistein-containing diet (Figure 7). Zymo-
graphic analysis also showed a significant decrease in pro–
MMP-9 in the conditioned medium from genistein-treated
PC3 cells compared to control [25]. These results clearly
suggest that genistein inhibited mRNA transcription and
protein levels ofMMPs, especiallyMMP-9, in vitro and in vivo.
Discussion
Genistein has been shown to inhibit cell growth in a wide
variety of cancer cells through regulation of several cell
signal transduction pathways [18–21,25]. Here, we demon-
strated that genistein significantly inhibits the growth of PC3
prostate cancer cells in culture, and also the growth of PC3
bone tumors in the SCID-hu model of prostate cancer bone
metastasis. These preclinical data suggest that genistein
Figure 2. (A) Inhibitory effects of genistein on the growth of bone tumors formed by PC3 cells in SCID-hu mice (Control, n = 6; Prevention, n = 7; Intervention, n = 7).
(B and C) Ex vivo bone tumor X-ray showing more osteolysis and tumor growth in the control group (B) than in the prevention group (C).
Table 2A. Numbers of Genes Showing z2-Fold Changes in PC3 Bone
Tumors After Genistein Treatment.
Prevention Intervention
P1 P2 I1 I2
Up 582 327 242 211
Down 66 49 46 31
Total 648 376 288 242
P1, P2: PC3 bone tumors in mice in the prevention group; I1, I2: PC3 bone
tumors in mice in the intervention group.
Table 2B. Numbers of Altered Genes in Different Categories in PC3 Bone
Tumors After Genistein Treatment.
Up Down
Apoptosis 12 1
Cell cycle arrest,
negative regulation of
cell proliferation, and transcription
13 0
Signal transduction, chemotaxis 10 7
Regulation of transcription and
protein biosynthesis
11 10
Oncogenesis 8 4
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may have beneficial effects in patients with prostate cancer
bone metastasis.
We have found that the inhibitory effects of genistein
in vitro were mediated by a large number of genes that are
related to the control of carcinogenesis, cell survival, and
physiological behaviors; these results have been published
previously [26]. However, little is known regarding the gene
expression profiles of prostate cancer cells after in vivo
genistein treatment. In order to investigate the molecular
effects of genistein on human prostate cancer bone metas-
tasis, in this study, we utilized the high-throughput gene chip
to determine gene expression profiles in experimental pros-
tate cancer bone tumors created by injecting PC3 cells, and
to analyze the alteration of these profiles after exposing
tumor-bearing animals to dietary genistein.
From microarray analysis with pathway-related annota-
tion (Figure 3, Tables 2B and 3), we found that the mole-
cular response to genistein in PC3 bone tumors involved
inhibition of expression of some genes that are related to
signal transduction, chemotaxis, transcription, protein bio-
synthesis, oncogenesis, and metastasis. However, genistein
upregulated some genes critical to the induction of apopto-
sis, cell cycle arrest, and negative regulation of cell prolifer-
ation and transcription. For example, DNA fragment factor
is a caspase-activated DNase and has been found to cleave
DNA in the apoptotic processes [34]. Granzyme A, pro-
grammed cell death 4 (PDCD4), and apoptosis-related pro-
tein (APG) also play important roles in the induction of
apoptosis [35–37]. Secreted frizzled-related protein 4
(SFRP4) has been found to be involved in oncogenesis by
regulating Wnt signaling pathway [38]. In vivo, genistein up-
regulated the expression of DNA fragment factor, Granzyme
A, PDCD4, and APG, and downregulated SFRP4, suggest-
ing the effect of genistein on the induction of apoptotic
Table 3. Fold Changes of Specific Genes in PC3 Bone Tumors in SCID-hu Mice Treated with Genistein.
Gene Prevention Intervention
Increase
Apoptosis
NM 004849.1 Homo sapiens APG5 (autophagy 5, Staphylococcus cerevisiae) – like (APG5L) 2.6 NC
NM 014456.1 H. sapiens programmed cell death 4 (PDCD4) 2.3 NC
BF433902 tumor necrosis factor receptor superfamily, member 11b (osteoprotegerin) 2.1 NC
NM 002546.1 tumor necrosis factor receptor superfamily, osteoprotegerin 2.0 NC
NM 006144.2 H. sapiens granzyme A 2.6 NC
NM 004402.1 H. sapiens DNA fragmentation factor (caspase-activated DNase) 2.5 2.5
AF001294.1 H. sapiens IPL (IPL) mRNA 2.1 NC
AF293841.1 H. sapiens apoptosis-related protein (APG5L) 2.8 NC
NM 022037.1 H. sapiens TIA1 cytotoxic granule-associated RNA-binding protein 2.1 NC
AF091627.1 H. sapiens CUSP mRNA 2.1 NC
AB037736.1 H. sapiens mRNA for KIAA1315 protein 2.1 1.7
NM 013229.1 H. sapiens apoptotic protease-activating factor (APAF1) NC 2.6
Cell cycle arrest, negative regulation of cell proliferation, and transcription
N23018 C-terminal binding protein 2 2.5 2.3
NM 003591.1 H. sapiens cullin 2 2.0 NC
NM 004585.2 H. sapiens retinoic acid receptor responder 3 2.5 NC
NM 020310.1 H. sapiens MAX-binding protein (MNT) 2.3 NC
BF673013 spectrin SH3 domain-binding protein 1 2.1 NC
NM 015895.1 H. sapiens geminin (LOC51053) 2.0 1.7
NM 003451.1 H. sapiens zinc finger protein 177 (ZNF177) 2.1 NC
BE046521 cut (Drosophila) – like 1 (CCAAT displacement protein) 2.0 NC
NM 004992.2 H. sapiens methyl CpG-binding protein 2 (MECP2) NC 3.7
Decrease
Signal transduction, chemotaxis
AW089415 SFRP4 2.1 1.1
NM 003014.2 H. sapiens SFRP4 2.8 1.6
BF304996 regulator of G-protein signalling 16 2.5 NC
NM 004887.1 H. sapiens small inducible cytokine subfamily B, member 14 1.4 2.3
NM 002984.1 H. sapiens small inducible cytokine A4 2.0 1.4
L35594.1 human autotaxin mRNA 2.1 1.1
Regulation of transcription and protein biosynthesis
NM 014660.1 H. sapiens KIAA0783 gene product (KIAA0783) 2.5 3.7
AF022654.1 H. sapiens homeodomain protein (OG12) mRNA 2.0 2.0
NM 012082.2 H. sapiens friend of GATA2 (FOG2) 8.0 NC
AK026674.1 H. sapiens cDNA: FLJ23021 fis, similar to HUMSEF21B 2.0 1.4
BC000023.1 H. sapiens, ribosomal protein S19 2.3 2.1
BF680255 ribosomal protein S11 2.3 4.0
AW302047 ribosomal protein S10 2.1 2.6
Oncogenesis
BC000023.1 H. sapiens, ribosomal protein S19 2.3 2.1
AW089415 SFRP4 2.1 1.1
NM 003014.2 H. sapiens 2.8 1.6
BF673699 v-Ki-ras2 Kirsten rat sarcoma 2 viral oncogene 1.3 2.0
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processes in vivo. Our results demonstrated that the
inhibition of tumor growth in vivo by genistein was associ-
ated with alterations in expression of a large number of
genes critically involved in the control of carcinogenesis,
cell survival, and physiological behaviors. However, genis-
tein also upregulated several genes related to signal
transduction, transcription, protein biosynthesis, and onco-
genesis, some of which may promote cell survival. More
studies are needed and are ongoing in our laboratory to
address this variation in vivo.
More importantly, we found that dietary genistein also
downregulated the expression of multiple metastasis-related
Figure 4. Cluster map of MMP gene expression analyzed by cDNA microarray. (A) Different levels of MMP mRNA expression in PC3 cells grown in culture, PC3
bone tumors, and PC3 subcutaneous tumors. (B and C) The expression of MMP mRNA was inhibited by genistein treatment both in vivo (B) and in vitro (C) (P1,
P2: PC3 bone tumors grown in mice in the prevention group; I1, I2: PC3 bone tumors grown in mice in the intervention group; 6 h, 36 h, 72 h: PC3 cells treated with
50 M genistein for 6, 36, and 72 hours).
Figure 3. Effects of genistein on pathway-related gene expression analyzed and visualized by GenMAPP software integrated with cDNA microarray data (positive
value: increase in fold change; negative value: decrease in fold change).
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genes, including many MMPs. In particular, we found that
dietary genistein inhibited the expression of MMP-2, MMP-9,
MMP-11, MMP-13, MMP-14, and MT-MMP. These preclin-
ical data corroborate our findings in vitro as reported previ-
ously [25,26]. MMPs have been shown by numerous
investigators to play a prominent role in metastasis [11,12].
Classically, MMP-2 and MMP-9, otherwise known as the
gelatinases, have been implicated in metastasis because of
their role in degrading basement membrane collagen. In-
creased expression of other MMPs, such as MMP-13 and
MMP-14, has been demonstrated in many different human
cancers [11,12]. For example, MMP-14, a membrane-type
MMP also known as MT1-MMP, has been shown to mediate
cell invasion in vitro and in vivo [39].
We and others have shown that MMP activity plays
an important role in metastasis specifically to the bone
[11,14,15]. MMP activity is known to play a role in both
normal and cancer-induced bone remodeling. Bone remod-
eling results in the release of various bioactive factors
embedded in the bone extracellular matrix; these factors
stimulate the local proliferation of tumor cells. Thus, en-
hanced MMP activity in bone tissues associated with the
presence of tumor cells may be one of the factors involved in
the so-called ‘‘vicious cycle’’ hypothesis [5] in which bone
matrix turnover and metastatic tumor growth are linked in a
positive feedback loop. The enhanced MMP activity in bone
metastasis may emanate from many cell types such as
tumor cells, stromal cells, osteoclasts, and osteoblasts.
Supporting this hypothesis, we previously found that small
molecule pharmaceutical inhibitors of MMP activity reduced
osteoclast recruitment, prevented bone matrix degradation,
and reduced prostate cancer cell proliferation in the human
bone implanted in SCID mice [14]. These data have been
replicated in other models of bone metastasis [15].
The effects of dietary genistein on bone tumor growth and
associated osteolysis in the current study are strikingly
similar to our findings with the MMP inhibitor [14]. Our data
Table 4. Fold Changes of MMP gene Expression in PC3 Bone Tumors in
Mice Fed Genistein Diet Compared to Mice Fed Control Diet.
Genes P1/C P2/C I1/C I2/C
Z48481 mRNA for membrane-type
matrix MMP-1
1.2 1.2 1.1 0
NM 004530.1 H. sapiens
matrix MMP-2
1.1 1.1 1.1 0
NM 004995.2 H. sapiens
matrix MMP-14
1.5 1.2 1.1 0
NM 005940.2 H. sapiens
matrix MMP-11
1.5 1.3 0 1.1
NM 004994.1 H. sapiens
matrix MMP-9
2.5 1.7 1.2 1.1
NM 002421.2 H. sapiens
matrix MMP-1
0 0 0 0
NM 002426.1 H. sapiens
matrix MMP-12
0 0 0 0
NM 002427.2 H. sapiens
matrix MMP-13
1.3 2.5 1.5 2.6
NM 004142.1 H. sapiens
matrix MMP-like 1
0 0 0 0
P1, P2: bone tumors in the prevention group; I1, I2: bone tumors in the
intervention group; C: bone tumor in the control group.
Figure 5. Real-time RT-PCR analysis of MMP-9 genes. Comparative analysis shows the downregulation of MMP-9 mRNA expression in PC3 cells grown in culture
(n = 3, P = .0199) (A) and in PC3 bone tumor in SCID-hu mice (n = 3, P < .01) (B) after genistein treatment compared to control. Real-time RT-PCR melting curve
shows that the PCR products of MMP-9 (C) and GAPDH (D) are pure (only one peak).
Figure 6. MMP-9 promoter transfection and CAT assay show that the activity
of MMP-9 promoter was inhibited by genistein treatment (n = 2, P = .0035).
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suggest that dietary genistein leads to diminished MMP
activity by limiting increases in MMP gene expression asso-
ciated with the presence of cancer cells in the bone. De-
crease in overall MMP gene expression (in multiple cell
types) ultimately limits tumor-induced bone matrix degrada-
tion. Controlling the rate of bone matrix turnover diminishes
the expansion of tumor within bone. This mechanism seems
more likely than a direct effect of genistein on the prolifera-
tion of tumor cells because the serum concentration of
genistein achieved in the mice by dietary manipulations
appears to be below the levels required for a direct effect
on tumor cells. One possible mechanism underlying the
modulation of MMP gene expression involves the NF-nB
transcription factor. Previously, we showed that genistein
inhibited NF-nB DNA-binding activity [21]. Because there is a
NF-nB–binding site in the promoter of MMP-9 (Figure 3), the
inhibition of NF-nB DNA-binding activity by genistein could
be one of the molecular mechanisms by which genistein
inhibits MMP-9 gene expression in various types of cells.
Genistein may regulate cancer-induced bone matrix turn-
over by additional mechanisms. We found that dietary gen-
istein upregulated the expression of OPG in PC3 bone
tumors, suggesting an inhibitory effect of genistein on oste-
oclast formation. Metastatic cancer cells are known to re-
lease RANKL and OPG into the bone microenvironment,
which act on osteoblastic stromal cells to regulate the
production of functioning osteoclasts [5,16]. RANKL stimu-
lates the formation and differentiation of osteoclasts by
binding to its receptor, RANK, expressed in osteoblastic
stromal cells [5,16]. OPG is a decoy receptor that prevents
binding of RANKL to RANK by competitive binding to
RANKL, leading ultimately to the inhibition of osteoclast
formation, survival, and activity [16,40] in the presence of
cancer cells. Supporting the ‘‘vicious cycle’’ hypothesis, OPG
shows activity for inhibition of bone tumor growth [41,42].
Zhang et al. [9] reported that OPG inhibited prostate cancer–
induced osteoclastogenesis and prevented prostate tumor
growth in the bone. A recent study also showed that OPG
decreased human prostate cancer burden in human adult
bone implanted into SCID mice [8]. Thus, upregulation of
OPG may be another mechanism by which genistein limits
bone metastasis.
Apart from MMPs, urokinase plasminogen activator
(uPA), its receptor (urokinase plasminogen activator recep-
tor, uPAR), proteinase M, and protease-activated receptor-2
(PAR-2) are important genes in the processes of tumor cell
invasion andmetastasis [43–45]. The results from our in vitro
study also showed that genistein downregulated the expres-
sion of uPA, uPAR, proteaseM, and PAR-2, and upregulated
the expression of connective tissue growth factor and con-
nective tissue activation peptide [25,26], suggesting that
genistein may inhibit invasion and metastasis of PC3 pros-
tate cancer cells by multiple mechanisms. The lower con-
centration of genistein achieved in vivo and complex tumor
tissues with multiple cell types might be the reasons why we
did not observe significant effects of genistein on the expres-
sion of uPA, uPAR, protease M, and PAR-2 in vivo.
In conclusion, dietary genistein regulated the expression
of metastasis-related genes and significantly inhibited the
growth of PC3 bone tumors in an animal model of human
prostate cancer bone metastasis. These results suggest that
genistein could be a promising agent for the prevention and/
or treatment of prostate cancer and its metastasis. This
information could also be exploited for devising chemopre-
ventive and/or therapeutic strategies against prostate can-
cer, particularly for metastatic prostate cancer for which
there is currently no curative therapy. However, the signifi-
cance of genistein-induced alterations of many of genes in
SCID-hu in vivo model requires further in-depth studies in
order to determine their causative role in antitumor and
antimetastasis effects of genistein on prostate cancer.
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